IP Library Granted Patent US 11,370,788
Granted Patent B2
US 11,370,788 · App. 15/733,519 · Granted Jun 28, 2022

Substituted imidazo[4,5-c]quinoline compounds with an N-1 branched group

Inventors: George W. Griesgraber (Eagan, MN); Kevin J. Bechtold (St. Paul, MN)
Assignee: 3M Innovative Properties Company
C07D471/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,370,788
App. No.
15/733,519
Granted
Jun 28, 2022
Kind
B2
Abstract

Imidazo[4,5-c]quinoline compounds having a substituent that is attached at the N−1 position by a branched group, single enantiomers of the compounds, pharmaceutical compositions containing the compounds, and methods of making the compounds are disclosed. Methods of use of the compounds as immune response modifiers, for inducing cytokine biosynthesis in humans and animals, and in the treatment of diseases including infectious and neoplastic diseases are also disclosed.

Claims (21)

1. A compound of Formula (I), or salt thereof:

wherein:

n is an integer of 0 or 1;

R is selected from the group consisting of halogen, hydroxy, alkyl, and alkoxy;

R 1 is —C 1-3 alkylene-O—C 1-3 alkyl;

R 2 is selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, n-butyl, —CH 2 OCH 3 , —CH 2 OCH 2 CH 3 , and —CH 2 CH 2 OCH 3 ; and

R 3 is alkyl, aralkyl, wherein the alkyl or alkyl portion of the aralkyl can be optionally interrupted by one or more non-peroxidic —O— atoms, and wherein the aryl portion of the aralkyl can be optionally substituted with halogen, hydroxy, alkyl, alkoxy, or combinations thereof.

2. The compound or salt of claim 1 , which is a compound of Formula (II), or salt thereof:

3. The compound or salt of claim 1 , which is a compound of Formula (III), or salt thereof:

4. The compound or salt of claim 3 , wherein the O—R 3 group is in the para position.

5. The compound or salt of claim 1 , wherein R is selected from the group consisting of halogen, hydroxy, —C 1-7 alkyl, and —C 1-7 alkoxy.

6. The compound or salt of claim 1 , wherein n is 0.

7. The compound or salt of claim 1 , wherein R 1 is —CH 2 OCH 3 or —CH 2 OCH 2 CH 3 .

8. The compound or salt of claim 1 , wherein R 2 is selected from the group consisting of hydrogen, methyl, and ethyl.

9. The compound or salt of claim 1 , wherein R 3 has at least 4 carbon atoms and up to 12 carbon atoms.

10. The compound or salt of claim 1 , wherein R 3 is —C 4-12 alkyl.

11. The compound or salt of claim 1 , wherein R 3 is —CH 2 -phenyl.

12. The compound or salt of claim 1 for use as a vaccine adjuvant.

13. A method of inducing biosynthesis of IFN-alpha in a human or animal comprising administering an effective amount of a compound or salt of claim 1 to the human or animal.

14. A method of inducing biosynthesis of TNF-alpha in a human or animal comprising administering an effective amount of a compound or salt of claim 1 to the human or animal.

15. A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 1 in combination with a pharmaceutically acceptable carrier.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2024
From: 3M INNOVATIVE PROPERTIES COMPANY
To: SOLVENTUM INTELLECTUAL PROPERTIES COMPANY
Reel/Frame 066433/0049 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 19, 2020
From: GRIESGRABER, GEORGE W.; BECHTOLD, KEVIN J.
To: 3M INNOVATIVE PROPERTIES COMPANY
Reel/Frame 053536/0692 →